Levonorgestrel News and Research

RSS

Traces of many medicines found in fish swimming in treated waste water

Researchers at Ume- University and the Sahlgrenska Academy at the University of Gothenburg, Sweden, have discovered that traces of many medicines can be found in fish that have been swimming in treated waste water. One such medicine, the hormone levonorgestrel, was found in higher concentrations in the blood of fish than in women who take the contraceptive pill. Elevated levels of this hormone can lead to infertility in fish.

5 Apr 2010

Watson Pharmaceuticals files ANDA with FDA seeking approval to market LoSeasonique

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.10 mg/0.02 mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries, Ltd.

9 Jan 2010

Sosei and ASKA Pharmaceuticals sign distribution agreement

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

2 Nov 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

Teva announces availability of its Plan B One-Step emergency contraceptive over-the-counter

Teva Women’s Health, Inc. announced today that its Plan B® One-Step (levonorgestrel) tablet, 1.5 mg emergency contraceptive is now available at licensed U.S. retail pharmacies. Approved by the U.S. Food and Drug Administration (FDA) on July 10, Plan B® One-Step can help prevent an unintended pregnancy after unprotected sex or contraceptive failure with just one pill in one dose.

16 Sep 2009

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Levonorgestrel Tablets, 0.75 mg for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17.

29 Aug 2009

Emergency contraceptive tablet to help prevent an unintended pregnancy

There is good news for college students as they head back to campus this fall. A new emergency contraceptive, Plan B® One-Step (levonorgestrel) tablet, 1.5 mg, is now available at the local pharmacy for all students 17 and older.

24 Aug 2009

FDA approves generic emergency contraceptive Plan B (levonorgestrel) tablets

The U.S. Food and Drug Administration today approved the first generic version of the emergency contraceptive Plan B (levonorgestrel) tablets, 0.75 mg. The generic product will be available by prescription only for women ages 17 and under.

24 Jun 2009

Watson Pharmaceuticals files application for generic LYBREL

Watson Pharmaceuticals, Inc. has confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its Levonorgestrel and Ethinyl Estradiol tablets, USP (0.09 mg/0.02 mg) extended-cycle oral contraceptive product prior to the expiration of patents owned by Wyeth.

14 Mar 2008

Watson Pharmaceuticals files application for generic SEASONIQUE

Watson Pharmaceuticals, Inc. has confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral contraceptive product, prior to the expiration of patents owned by Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc.

6 Mar 2008

FDA soon to approve contraceptive pill Lybrel that also stops periods

The Food and Drug Administration (FDA) in the United States is about to approve a birth control pill with a double whammy.

21 May 2007

Ban called for on newer birth control pills

The advocacy group Public Citizen has filed a petition with the Food and Drug Administration (FDA) demanding that the sale of some of the newer birth control pills be banned.

6 Feb 2007

Women's health policy highlights

Highlights recently released from journal articles on women's health issues

24 Aug 2006

Intrauterine device as satisfactory as surgery for treating heavy menstrual bleeding

For women who experience heavy periods, surgery is more effective than oral or intrauterine medication in reducing volume of bleeding at one year, according to a systematic review of studies.

11 May 2006

Study shows rapid return to menstrual flow once oral contraception stopped

A study by a Columbia University Medical Center researcher shows that 99 percent of participants experienced either a return to menstruation or became pregnant within 90 days after stopping an investigational, low-dose oral contraceptive taken every day without placebo.

8 May 2006

Easier access to emergency contraception would not increase the risk of STDs

Making it easier to obtain emergency contraception would not increase unprotected intercourse, lead to abandonment of regular contraception, or increase the risk of sexually transmitted infections (STIs), according to a study in the January 5 issue of JAMA.

5 Jan 2005

Levonorgestrel-Releasing Intrauterine System Lessens Decrease Hysterectomy Rates in Finland

In the treatment of heavy menstrual bleeding, levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy improves equally health related quality of life, but the costs after 5 years are significantly lower in women whose treatment was started with IUS.

23 Mar 2004